𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Discussion: Development of Experimental Models for Ovarian Cancer

✍ Scribed by Thomas C. Hamilton; Jeanne L. Becker; Barry M. Kacinski; Santo V. Nicosia; Gustavo Rodriquez

Book ID
112251840
Publisher
Elsevier Science
Year
2003
Tongue
English
Weight
32 KB
Volume
88
Category
Article
ISSN
0090-8258

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Development of human prostate cancer mod
Development of human prostate cancer models for chemoprevention and experimental therapeutics studies
✍ Chung, Leland W.K.; Zhau, Haiyen E.; Wu, Tony T. πŸ“‚ Article πŸ“… 1997 πŸ› John Wiley and Sons 🌐 English βš– 126 KB πŸ‘ 2 views

The progression of human prostate cancer from histomorphologic to clinical expression often requires several decades. This study emphasizes the importance of developing relevant human prostate cancer models to study the molecular events leading to prostate cancer progression. These models will provi

Risk models for familial ovarian and bre
Risk models for familial ovarian and breast cancer
✍ Antonis C. Antoniou; Simon A. Gayther; John F. Stratton; Bruce A.J. Ponder; Doug πŸ“‚ Article πŸ“… 2000 πŸ› John Wiley and Sons 🌐 English βš– 106 KB πŸ‘ 2 views

We investigated risk models for the inherited susceptibility of breast and ovarian cancer, using data from both high-risk families and a population based series of ovarian cancer. The first data set consisted of 112 families containing two or more relatives with epithelial ovarian cancer. BRCA1 and

Immunotherapy of ovarian carcinoma. An e
Immunotherapy of ovarian carcinoma. An experimental model
✍ Stanley E. Order; Valentina Donahue; Robert Knapp πŸ“‚ Article πŸ“… 1973 πŸ› John Wiley and Sons 🌐 English βš– 625 KB

T h e specificity of a tumor antigen of an experimental ovarian carcinoma was determined by immunofluorescence, cytotoxicity, and immunoelectrophoresis using a n absorbed heterologous tumor antiserum. Tumor controls and normal rabbit sera controls were compared to tumor antiserum-treated recipients.